Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | POLB | P06746 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | APEX1 | P27695 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 6/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3441076 | 1.00 | ALDH1A1 (0.66) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL4604590 | 0.95 | ALDH1A1 (0.68) | ALDH1A1POLBKDM4ETP53GLA | |
| Hydrochloric Acid SCHEMBL4604330 | 0.94 | ALDH1A1 (0.66) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL5828001 | 0.86 | ALDH1A1 (0.68) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL30587607 | 0.86 | ALDH1A1 (0.68) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL5828004 | 0.86 | ALDH1A1 (0.68) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL28775935 | 0.85 | POLB (0.66) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL9568619 | 0.85 | MAPK1 (0.65) | CYP2D6MAPK1L3MBTL1KMT2AMEN1 | |
| SCHEMBL24130616 | 0.84 | ALDH1A1 (0.64) | ALDH1A1POLBKDM4ETP53GLA | |
| SCHEMBL9899331 | 0.84 | POLB (0.64) | ALDH1A1POLBKDM4ETP53GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3467096-B1 | EUKARYOTIC MICROORGANISMS FOR PRODUCING LIPIDS AND ANTIOXIDANTS | DSM NUTRITIONAL PRODUCTS AG (CH) | 2022-01-12 | — | — | EP | disclosed |
| US-10435725-B2 | Eukaryotic microorganisms for producing lipids and antioxidants | DSM NUTRITIONAL PRODUCTS AG (CH) | 2019-10-08 | — | — | US | disclosed |
| US-20190169660-A1 | EUKARYOTIC MICROORGANISMS FOR PRODUCING LIPIDS AND ANTIOXIDANTS | DSM NUTRITIONAL PRODUCTS AG (CH) | 2019-06-06 | — | — | US | disclosed |
| EP-3467096-A1 | EUKARYOTIC MICROORGANISMS FOR PRODUCING LIPIDS AND ANTIOXIDANTS | DSM Nutritional Products AG (CH) | 2019-04-10 | — | — | EP | disclosed |
| EP-3238543-B1 | EUKARYOTIC MICROORGANISMS FOR PRODUCING LIPIDS AND ANTIOXIDANTS | DSM NUTRITIONAL PRODUCTS AG (CH) | 2019-03-20 | — | — | EP | disclosed |
| US-20170335356-A1 | EUKARYOTIC MICROORGANISMS FOR PRODUCING LIPIDS AND ANTIOXIDANTS | DSM NUTRITIONAL PRODUCTS AG (CH) | 2017-11-23 | — | — | US | disclosed |
| EP-3238543-A1 | EUKARYOTIC MICROORGANISMS FOR PRODUCING LIPIDS AND ANTIOXIDANTS | DSM Nutritional Products AG (CH) | 2017-11-01 | — | — | EP | disclosed |
| US-9719116-B2 | Eukaryotic microorganisms for producing lipids and antioxidants | DSM NUTRITIONAL PRODCUTS AG (CH) | 2017-08-01 | — | — | US | disclosed |
| EP-2468847-B1 | EUKARYOTIC MICROORGANISMS FOR PRODUCING LIPIDS AND ANTIOXIDANTS | DSM NUTRITIONAL PRODUCTS AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| EP-2447356-B1 | Eukaryotic microorganisms for producing lipids and antioxidants | DSM NUTRITIONAL PRODUCTS AG (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2006117675-A1 | FATTY ACID-BENZENEDIOL DERIVATIVES AND METHODS OF MAKING AND USING THEREOF | OCEAN NUTRITION CANADA LTD. (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006109194-A2 | CHROMIUM-FATTY ACID COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | OCEAN NUTRITION CANADA LTD. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006078284-A2 | METHODS AND COMPOSITIONS RELATED TO ANTIVIRAL THERAPY USING ALGAE AND CYANOBACTERIA | UNIVERSITY OF SOUTH CAROLINA (US) | 2006-07-27 | — | — | WO | disclosed |
| EP-0599444-B1 | Dual action inhibitors | SQUIBB & SONS INC (US) | 1998-01-28 | — | — | EP | disclosed |
| EP-0783002-A2 | Dual action inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1997-07-09 | — | — | EP | disclosed |
| EP-0599444-A1 | Dual action inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0133225-B1 | PEPTIDE DERIVATIVES AND THEIR SALTS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, PROCESS AND INTERMEDIATES FOR THEIR PRODUCTION | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1988-10-19 | — | — | EP | disclosed |
| EP-0133225-A2 | Peptide derivatives and their salts, pharmaceutical preparations containing them, process and intermediates for their production | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1985-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | ALDH1A1 2937/4885POLB 2061/4885KDM4E 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.